AI Article Synopsis
- CAR therapy is a promising cancer treatment that has helped many people, especially with blood cancers.
- Even though it's been successful, there are still many things that can be improved, like how the therapy is made and how it's used in hospitals.
- This chapter talks about what changes can make CAR therapy better and how it could be used for diseases beyond just blood cancers.
Article Abstract
Chimeric antigen receptor (CAR) is probably one of the most successful proposals for cancer treatment, especially hematological diseases for which several Advanced Therapies Medicinal Products (ATMP) have been approved worldwide by drug agencies. But, despite this unprecedented success in the oncology and cell/gene therapy fields, there are a lot of aspects that could (and should) be improved in the multiple aspects that involve this complex therapy: from the design of the chimeric molecule to the clinical protocols of use of the engineered T-cells, including even the regulatory rules that they are currently restricting the development of these hopeful therapies. In this chapter, we will try to summarize the main aspects that can (and probably should) be improved for the expansion of immunotherapy with CAR proposals beyond onco-hematology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.ircmb.2022.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!